Vendor comparison · 2026
Survodutide vendors: 1 compared on COAs and price
MetabolicAlso known as BI 456906
Evidence tier
Moderate published literature
70 publications over 2 years · trials not yet curated
- Vendors carrying it
- 1
- 1 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- $9.00
- peer median $9.00
- Publications located
- 70
- researched since 2024
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Survodutide certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. The lowest listed price is $9.00 per mg at Good Science Bio, against a peer median of $9.00. 1 vendor carrying Survodutide is compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Survodutide
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Good Science Bio | 67.571% | $9.00 (100%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Survodutide is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Survodutide names a laboratory this index could identify.
Every certificate record
No certificate record for Survodutide is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2024 — 2 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
70 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
1 of 1 listing vendor publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Survodutide?
A dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic (MASH) liver disease.
Studied in published research for obesity and metabolic liver disease.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in human phase 2 trials for weight loss and liver disease. PepIndex does not evaluate clinical significance and does not describe administration.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — The New England journal of medicine (2024)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2024).
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial — The lancet. Diabetes & endocrinology (2024)
Peer-reviewed article indexed in PubMed, published in The lancet. Diabetes & endocrinology (2024).
- Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial — Diabetologia (2024)
Peer-reviewed article indexed in PubMed, published in Diabetologia (2024).
- Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial — JACC. Heart failure (2024)
Peer-reviewed article indexed in PubMed, published in JACC. Heart failure (2024).
- Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction — Expert opinion on investigational drugs (2024)
Peer-reviewed article indexed in PubMed, published in Expert opinion on investigational drugs (2024).
- Survodutide Once Weekly for the Treatment of Adults with Obesity — The New England journal of medicine (2026)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2026).
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis — Journal of hepatology (2024)
Peer-reviewed article indexed in PubMed, published in Journal of hepatology (2024).
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) — Diabetes, obesity & metabolism (2026)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2026).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.